Vimentin at time of retinal repair may be biomarker for proliferative vitreoretinopathy
Click Here to Manage Email Alerts
NEW ORLEANS — Increased vimentin at the time of retinal detachment repair may help predict later development of proliferative vitreoretinopathy, according to a poster presentation at the American Academy of Ophthalmology meeting.
“Our study is the first to look into vitreous biomarker values at baseline retinal detachment surgery and prior to PVR formation,” Abtin Shahlaee, MD, said in the presentation. “In the present study, we demonstrated increased baseline vimentin in the human vitreous body of patients subsequently developing PVR.”
In a retrospective chart review of patients undergoing primary pars plana vitrectomy between 2014 and 2020, Shahlaee and colleagues compared vitreous samples from 13 patients who developed proliferative vitreoretinopathy (PVR) within 6 months with samples from 13 control patients matched for age, sex and ethnic background. Samples were stored at –80°C.
Baseline vimentin levels measured by Olink Oncology II immunoassay panel normalized protein expression (NPX) were statistically significantly elevated in patients who went on to develop PVR: 8.6 NPX vs. 6.4 NPX in the control group (P < .05).
Study limitations included small sample size and limited follow-up, the authors wrote.
“Further avenues that can be explored in this regard are biomarkers ranging from other intermediate filaments to a multitude of growth factors in cytokines and therapeutic targets using larger scale and possibly multicenter studies,” Shahlaee said.
Collapse
Shahlaee A, et al. Increased vimentin levels in vitreous fluid at the time of primary retinal detachment repair as a biomarker for subsequent development of proliferative vitreoretinopathy. Presented at: American Academy of Ophthalmology meeting; Nov. 12-15, 2021; New Orleans.
Read more about
Click Here to Manage Email Alerts